These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 38511195)

  • 21. The Effect of Geographic Location on Circannual Adrenocorticotropic Hormone Plasma Concentrations in Horses in Australia.
    Secombe CJ; Tan RHH; Perara DI; Byrne DP; Watts SP; Wearn JG
    J Vet Intern Med; 2017 Sep; 31(5):1533-1540. PubMed ID: 28661009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The "highs and lows" of the human brain on dopaminergics: Evidence from neuropharmacology.
    Martins D; Mehta MA; Prata D
    Neurosci Biobehav Rev; 2017 Sep; 80():351-371. PubMed ID: 28624433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutics for Equine Endocrine Disorders.
    Durham AE
    Vet Clin North Am Equine Pract; 2017 Apr; 33(1):127-139. PubMed ID: 28190613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabergoline for Cushing's disease: a large retrospective multicenter study.
    Ferriere A; Cortet C; Chanson P; Delemer B; Caron P; Chabre O; Reznik Y; Bertherat J; Rohmer V; Briet C; Raingeard I; Castinetti F; Beckers A; Vroonen L; Maiter D; Cephise-Velayoudom FL; Nunes ML; Haissaguerre M; Tabarin A
    Eur J Endocrinol; 2017 Mar; 176(3):305-314. PubMed ID: 28007845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiographic evaluation in clinical practice of the types and stage of incisor tooth resorption and hypercementosis in horses.
    Henry TJ; Puchalski SM; Arzi B; Kass PH; Verstraete FJM
    Equine Vet J; 2017 Jul; 49(4):486-492. PubMed ID: 27862232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine Disease in Aged Horses.
    Durham AE
    Vet Clin North Am Equine Pract; 2016 Aug; 32(2):301-15. PubMed ID: 27449391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
    McFarlane D; Banse H; Knych HK; Maxwell LK
    J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
    Spelta CW; Axon JE
    Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seasonal variation in results of diagnostic tests for pituitary pars intermedia dysfunction in older, clinically normal geldings.
    Schreiber CM; Stewart AJ; Kwessi E; Behrend EN; Wright JC; Kemppainen RJ; Busch KA
    J Am Vet Med Assoc; 2012 Jul; 241(2):241-8. PubMed ID: 22765372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.
    Rohrbach BW; Stafford JR; Clermont RS; Reed SM; Schott HC; Andrews FM
    J Vet Intern Med; 2012; 26(4):1027-34. PubMed ID: 22524260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A survey of health care and disease in geriatric horses aged 30 years or older.
    Ireland JL; McGowan CM; Clegg PD; Chandler KJ; Pinchbeck GL
    Vet J; 2012 Apr; 192(1):57-64. PubMed ID: 21550271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equine pituitary pars intermedia dysfunction.
    McFarlane D
    Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cross-sectional study of geriatric horses in the United Kingdom. Part 2: Health care and disease.
    Ireland JL; Clegg PD; McGowan CM; McKane SA; Pinchbeck GL
    Equine Vet J; 2011 Jan; 43(1):37-44. PubMed ID: 21143632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A survey of aged horses in Queensland, Australia. Part 1: management and preventive health care.
    McGowan TW; Pinchbeck G; Phillips CJ; Perkins N; Hodgson DR; McGowan CM
    Aust Vet J; 2010 Nov; 88(11):420-7. PubMed ID: 20958281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equine odontoclastic tooth resorption and hypercementosis.
    Staszyk C; Bienert A; Kreutzer R; Wohlsein P; Simhofer H
    Vet J; 2008 Dec; 178(3):372-9. PubMed ID: 19010701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
    Pivonello R; De Martino MC; Cappabianca P; De Leo M; Faggiano A; Lombardi G; Hofland LJ; Lamberts SW; Colao A
    J Clin Endocrinol Metab; 2009 Jan; 94(1):223-30. PubMed ID: 18957500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pituitary-targeted medical therapy of Cushing's disease.
    Alexandraki KI; Grossman AB
    Expert Opin Investig Drugs; 2008 May; 17(5):669-77. PubMed ID: 18447593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolactin and the hyperphagia of lactation.
    Woodside B
    Physiol Behav; 2007 Jul; 91(4):375-82. PubMed ID: 17498759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pituitary pars intermedia dysfunction: equine Cushing's disease.
    Schott HC
    Vet Clin North Am Equine Pract; 2002 Aug; 18(2):237-70. PubMed ID: 15635907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of season and sample handling on measurement of plasma alpha-melanocyte-stimulating hormone concentrations in horses and ponies.
    McFarlane D; Donaldson MT; McDonnell SM; Cribb AE
    Am J Vet Res; 2004 Nov; 65(11):1463-8. PubMed ID: 15566081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.